Peroxisome Proliferator-Activated Receptor- Is a Potent Target for Prevention and Treatment in
Human Prostate and Testicular Cancer
Table 3
Effects of troglitazone, 15-d-PGJ2 and GW9662 in viabity of human PC and TC cell lines.
5 M
10 M
20 M
40 M
Troglitazone
PC cell lines
LNCaP
72.4%
25.7%
12.6%
8.4%
PC3
48.6%
15.5%
14.7%
6.5%
DU-145
60.1%
35.1%
7.6%
7.7%
TC cell line
NEC-8
38.7%
35.3%
36.6%
38.1%
15-d-PGJ2
PC cell lines
LNCaP
78.9%
63.7%
22.4%
5.6%
PC3
69.7%
59.0%
34.1%
6.8%
DU-145
73.8%
59.3%
5.8%
5.8%
TC cell line
NEC-8
75.1%
66.7%
52.3%
46.8%
GW9662
PC cell lines
LNCaP
106.8%
112.4%
103.7%
106.2%
PC3
116.8%
118.6%
119.4%
120.2%
DU-145
122.6%
119.4%
117.8%
115.6%
TC cell line
NEC-8
108.4%
115.5%
110.6%
112.3%
The dose-response analysis of viability in human cancer cells treated with troglitazone, 15-d-PGJ2 and GW9662 (5–40 M, 48 hr) was measured by the MTT assay and expressed as % of control culture conditions ().
